MAB21L2

Across TCGA pan-cancer cohorts, MAB21L2 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated MAB21L2 data layer compared with 20 for mass-spec protein.

The strongest signal is observed in rectum adenocarcinoma (READ), where higher MAB21L2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated MAB21L2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

READ, COAD, and KIRC are the cancer types where MAB21L2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
READ	DFS	Median	All	0.082	0.799	<.001	15	view →
COAD	OS	Median	II,III,IV	0.231	0.612	.003	14	view →
KIRC	OS	Median	All	0.167	0.655	.038	12	view →
ESCA	DFS	Median	II,III,IV	0.082	0.523	<.001	12	view →
SARC	DFS	Median	All	0.024	0.611	<.001	6	view →
UCEC	DFS	Median	II,III,IV	0.915	0.439	.037	4	view →
SKCM	DFS	Median	All	0.483	0.199	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

MAB21L2–READ (DFS)

Open the READ breakdown →